Question 1
Difficulty: medium
How do you handle the intake, triage, and processing of an adverse event case from start to finish?
Sample answer
My approach is to treat intake as both a compliance step and a quality step. First, I confirm the minimum criteria for a valid case: an identifiable patient, an identifiable reporter, a suspect product, and an adverse event. Once that is established, I triage the case based on seriousness, expectedness, product type, and reporting timelines. I then review the source documentation carefully, reconcile any inconsistencies, and code the event and products accurately using the relevant standards. If information is missing, I follow up promptly and document every attempt. Before submission, I perform a quality check to make sure the narrative is clear, chronology makes sense, and the case is medically coherent. I’ve found that being thorough early prevents downstream corrections and audit issues. I also stay mindful of regulatory deadlines so quality never comes at the expense of timeliness.
Question 2
Difficulty: hard
Tell me about a time you identified a potential safety signal before it became a bigger issue.
Sample answer
In one role, I noticed a small but unusual cluster of similar complaints across several individual case safety reports for the same product. Each case alone seemed manageable, but when I looked at them together, the pattern suggested a possible signal worth escalating. I documented the cases carefully, compared the event terms, and reviewed the timelines and patient characteristics to see whether there was a plausible common thread. I then brought the trend to the attention of the safety physician and signal detection team with a concise summary rather than just raw data. That helped the team assess whether additional review or literature monitoring was needed. What I learned from that experience is that pharmacovigilance depends on curiosity and pattern recognition as much as process. A strong specialist does not just process cases; they notice when the data starts telling a larger story.
Question 3
Difficulty: medium
How do you ensure compliance with expedited reporting requirements such as 7-day or 15-day submissions?
Sample answer
I manage expedited reporting by building discipline into the workflow rather than relying on memory. As soon as a case is entered, I assess seriousness and any special regulatory triggers, then confirm the reporting clock based on the event date, receipt date, and available source information. I prioritize high-risk cases immediately and keep a clear view of due dates through trackers or case management systems. If I anticipate delays because of missing information or complex medical review, I escalate early instead of waiting until the deadline is close. I also make sure the narrative and causality assessment are supported by the source documents so the submission is both timely and defensible. In previous roles, I’ve worked closely with medical reviewers, vendors, and quality teams to avoid last-minute bottlenecks. For me, compliance is not just about speed; it is about maintaining accuracy under pressure and making sure nothing falls through the cracks.
Question 4
Difficulty: easy
Describe your experience with MedDRA coding and why accurate coding matters in pharmacovigilance.
Sample answer
Accurate MedDRA coding is essential because it directly affects case quality, signal detection, aggregate reporting, and the way safety data is interpreted across the organization. I approach coding by first understanding the clinical meaning of the reporter’s description, not just matching keywords. That helps me choose the most precise term and avoid overcoding or undercoding the event. I also consider whether a term should be coded as a symptom, diagnosis, procedure, or investigation finding, depending on the source. When the case involves multiple related events, I try to preserve the clinical picture while keeping the coding consistent with internal conventions. I’ve seen how poor coding can distort trend analysis or create noise in signal reviews, so I’m careful to document rationale when needed and align with coding guidelines. Strong coding, in my view, is not mechanical work; it requires clinical judgment, attention to detail, and consistency.
Question 5
Difficulty: medium
How would you handle a serious adverse event report with incomplete information and a very short timeline?
Sample answer
In that situation, I would first make sure the case is assessed against the reporting criteria as quickly as possible using the information already available. If it meets minimum criteria and seriousness is evident, I would not wait for a perfect dataset before starting the submission process. I would capture what is known accurately, clearly label unknowns, and document the gaps transparently. At the same time, I would initiate targeted follow-up for the missing critical details, focusing on items that could change the case interpretation, such as outcome, onset date, hospitalization details, or concomitant medications. I’d also communicate early with the relevant stakeholders so they understand the urgency. The key is balancing speed with discipline: protecting the submission deadline without introducing unsupported assumptions. I have found that a concise, well-documented partial report is far better than a late report that was delayed in pursuit of completeness.
Question 6
Difficulty: easy
What steps do you take to maintain high case quality when processing a large volume of reports?
Sample answer
When the volume is high, I rely on structure and prioritization so quality doesn’t drop. I start by sorting cases by urgency, especially serious and expedited reports, then I batch similar tasks together to reduce context switching. I use a consistent checklist for intake, medical review, coding, narrative quality, and submission readiness. That helps me avoid missing recurring details like dates, product exposure, reporter relationship, or follow-up requirements. I also build in quick self-checks before finalizing each case, because small errors often happen when people rush. If I notice a pattern of recurring issues, I adjust my process rather than just reacting case by case. For example, if product identification is often unclear, I would improve the intake questions or create a better reference guide. I’ve learned that high output and high quality are not opposites if you work methodically and keep your process disciplined.
Question 7
Difficulty: easy
How do you approach writing a clear and medically accurate case narrative?
Sample answer
I write narratives with the reader in mind, especially the medical reviewer, auditor, or regulator who may not know the original source details. I aim for a logical sequence: who the patient is, what product was involved, what happened, when it happened, what action was taken, and what the outcome was. I keep the language factual and avoid overinterpreting the reporter’s comments. If there are contradictions or gaps, I acknowledge them directly instead of trying to smooth them over. I also make sure the chronology is easy to follow, because that is often where confusion starts. A strong narrative should explain the event in a way that stands on its own even if the source documents are not immediately available. In my experience, the best narratives are concise but complete. They do not sound overly clinical or overly conversational; they sound accurate, organized, and fair to the data.
Question 8
Difficulty: hard
Tell me about a time you disagreed with a medical reviewer or colleague about case assessment. What did you do?
Sample answer
I once had a case where I believed the event met criteria for serious reporting, but a colleague initially felt it should be treated as non-serious because the documentation was limited. Rather than framing it as a debate, I walked through the source line by line and focused on the facts that supported the seriousness classification, including hospitalization details and the reported outcome. I also acknowledged the uncertainties in the record so the discussion stayed balanced. What helped most was keeping the conversation centered on regulatory criteria instead of personal opinions. In the end, we aligned on the more conservative and defensible approach, and the case was submitted appropriately. That experience reinforced that good pharmacovigilance work depends on respectful challenge and shared accountability. I’m comfortable being wrong, but I also believe concerns should be raised clearly when patient safety or compliance may be affected.
Question 9
Difficulty: medium
How do you stay current with pharmacovigilance regulations and industry expectations?
Sample answer
I stay current by combining formal and informal learning. I review updates from health authorities, internal SOP changes, and safety-related training materials on a regular basis. I also pay attention to inspection findings, trend discussions, and internal quality metrics because they often reveal where expectations are shifting in practice. When a regulatory update affects my work directly, I make sure I understand not only the rule but also the operational impact on case processing, timelines, and documentation. I’ve found that it helps to discuss changes with colleagues as well, because different teams may interpret implementation details differently at first. I also keep notes on recurring issues I see in cases, which helps me connect guidance to real workflow problems. Pharmacovigilance is a field where small details matter, so staying current is part of the job, not an extra task. It is what allows me to make confident decisions and reduce compliance risk.
Question 10
Difficulty: easy
Why are you interested in a Pharmacovigilance Specialist role, and what strengths would you bring to it?
Sample answer
I’m interested in pharmacovigilance because it sits at the intersection of patient safety, science, and operational precision. I like work that requires both critical thinking and accountability, and this role demands both every day. What motivates me most is the idea that careful case processing, signal awareness, and compliance discipline can contribute to safer medicine use. In terms of strengths, I bring strong attention to detail, a calm approach under deadline pressure, and the ability to communicate clearly with both technical and non-technical colleagues. I’m also comfortable working in structured systems and following process without losing sight of the clinical context. Just as importantly, I’m proactive about asking questions when something does not make sense, because I know that unclear assumptions can affect patient safety and reporting quality. I would bring reliability, sound judgment, and a steady focus on doing the work accurately the first time.
